Letermovir is approved by the FDA to prevent CMV in kidney transplant recipients.

Published Date: 09 Jun 2023

the U. Letermovir has received FDA approval to protect kidney transplant recipients from cytomegalovirus infection.

Read Full News

Latest News

Digital Sodium Intervention Improves Sodium Knowledge

A nurse-led digital intervention improves sodium knowledge in patients with chronic kidney disease but faces major adherence barriers, a study reports.

Deep Dive: The Evolving GLP-1 Class Overview

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

Todays Updates

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Can a Betting Market Offer Hope to a Cancer Patient?

As we embrace the power of collective knowledge, we must remember that numbers are just numbers

Rewriting the Future of Medicine; Cancer Cost Burden; Mental Health Toll of Cancer

News, features, and commentary about cancer-related issues

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

News, features, and commentary about cancer-related issues

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

"This specific formulation of daunorubicin and cytarabine is not the right choice," experts said

Post-Transplant Outcomes in Hodgkin Lymphoma Improved Over Time

Improvements primarily driven by reduction in incidence of relapse

Todays Updates

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk

Can a Betting Market Offer Hope to a Cancer Patient?

As we embrace the power of collective knowledge, we must remember that numbers are just numbers

Rewriting the Future of Medicine; Cancer Cost Burden; Mental Health Toll of Cancer

News, features, and commentary about cancer-related issues

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

News, features, and commentary about cancer-related issues

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

"This specific formulation of daunorubicin and cytarabine is not the right choice," experts said

Post-Transplant Outcomes in Hodgkin Lymphoma Improved Over Time

Improvements primarily driven by reduction in incidence of relapse

Latest News

A nurse-led digital intervention improves sodium knowledge in patients with chronic kidney disease but faces major adherence barriers, a study reports.

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

News All Time

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

Less frequent dosing could support better long-term adherence, says researcher

APOL1 Gene and Focal Segmental Glomerulosclerosis

Genetic variants tied to increased risk are only found in those of African decent

Make the Diagnosis: Chest Pain, Dyspnea, Palpitations, and More: What’s Her Diagnosis?

A 45-year-old woman presented to the emergency department with complaints of chest pain, heart palpitations that developed earlier that day, and dyspnea that began 3 days prior and had progressed. Can you diagnose the patient?

Rewriting What We Know About Kidney Transplant Rejection

Rewriting What We Know About Kidney Transplant Rejection

First Oral Carbapenem Approved for Complicated UTIs

Tebipenem pivoxil proved noninferior to IV imipenem-cilastatin in hospitalized patients

How Did a Patient Survive a Decade With Metastatic RCC?

Surgery had beneficial role

360 Dead in Outbreak; McConnell Still Hospitalized? FDA Rejects Kidney Disease Drug

Health news and commentary gathered by MedPage Today staff

US FDA Declines to Approve Unicycive's Kidney Disease Drug

Unicycive Therapeutics said on Tuesday the U.S. drug regulator has declined to approve its drug to ⁠treat elevated phosphate levels in chronic kidney disease patients on...

The Chatbot Will See You Now: A Crisis in Trust?

When healthcare feels out of reach, Europe’s patients are turning to AI for answers — and sometimes for the confidence to medicate themselves.

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Mineralys' Pill Cuts Blood Pressure in Kidney Disease Patients

Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented ⁠at a major European...

Project Aims for Awareness of APOL1-Mediated Kidney Disease

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations and medical trainees.

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Recommended News For You

Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

Early, virtual palliative care feasible for advanced lung cancer

Coffee and tea linked to lower head and neck cancer risk

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

MGRS Relapse-Free Survival Better With Maintenance Therapy

Radiation from CT scans could account for 5% of all cancer cases a year, study suggests

Recommended Articles For You

Practical Applications in Hematology Across Clinical Settings 

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control 

CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target 

Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

2.

New drug combination shows good results in patients with HPV-negative head and neck cancer

3.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

4.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

5.

Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant

1.

Environmental Carcinogen Exposure Screening: Advances, Clinical Implications, and Guideline-Based Approaches

2.

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies 

3.

Progressive Insights in Hematology in the Digital Era

4.

Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations

5.

The importance of understanding normal serum osmolality

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

2.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

3.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot